Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Olema Pharmaceuticals, Inc.

OLMA ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$7.02

▼ -4.62%

Market Cap $614.23M · Vol 538.79K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$614.23M

Small Cap

Div Yield

N/A

EPS Growth

-31.21%

YoY

RSI (14)

14.09

Momentum

Beta

2.08

vs Market

52W High

$36.19

80.60% below

52W Low

$6.66

5.41% above

Volume

538.79K

Avg 420.15K

P/B

4.25

Price-to-book

ROE

-36.61%

Return on equity

Free Float

97.63%

Public shares

Shariah Compliance8 STANDARDS

✗ Olema Pharmaceuticals, Inc. (OLMA) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does OLMA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-11.36%

-31.31%

-40.76%

-55.93%

YTD

-71.92%

-34.70%

-44.42%

-76.49%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-162,451,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-36.61%
ROA · ROIC	-33.00% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	4.25
P/FCF	N/A
EPS Growth	-31.21%
Outstanding Shares	87.50M

Technical Indicators

50-Day SMA	$9.92
200-Day SMA	$15.29
RSI (14)	14.09
Beta	2.08
52-Week High	$36.19
52-Week Low	$6.66

Volume Today	538.79K
Avg Daily Volume (30D)	420.15K
Relative Volume	1.28x
Volatility (10D)	38.94
Volatility (30D)	46.11
Free Float	97.63%

Analyst Consensus

BUY

Current Price $7.02

Mean Target $35.44

52W Low$6.66 52W High$36.19

Current

Target

$6.66 $36.19

Current Analyst target

+404.91% upside potential · 11 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00T5JMRV1

ISINUS68062P1066

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.32% ONC BeOne Medicines AG -0.38% 068270.KS Celltrion, Inc. -0.39% MEDP Medpace Holdings, Inc. -1.64% ABVX Abivax SA -0.83%

Company Profile

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a novel, orally available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD). It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Its second product candidate in clinical development, called OP-3136, is a novel, orally available small molecule that potently and selectively inhibits KAT6, an epigenetic target that is dysregulated in breast and other cancers.